2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
Planchard D, Wolf J, Solomon B, Sebastian M, Wermke M, Heist R, Sun J, Min Kim T, Reguart N, Sanmamed M, Felip E, Garrido P, Santoro A, Bootle D, Couillebault X, Gaur A, Mueller C, Poggio T, Yang J, Moschetta M, Dooms C. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer. Lung Cancer 2024, 197: 107964. PMID: 39383771, DOI: 10.1016/j.lungcan.2024.107964.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerBRAF-mutated non-small cell lung cancerLung cancerDose-escalation/dose-expansion studyTreatment-related adverse eventsAntitumor activityDose-limiting toxicityNRAS-mutant melanomaMEK1/2 inhibitor trametinibPartial responseInhibitor trametinibFrequent gradeSafety profileAdverse eventsPharmacodynamic effectsTrametinibGenetic alterationsMedian reductionPan-RAFIncreased lipasePatientsSecondary objectivesMRNA levelsEvaluate toleranceProtein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment
Orive D, Echepare M, Bernasconi-Bisio F, Sanmamed M, Pineda-Lucena A, de la Calle-Arroyo C, Detterbeck F, Hung R, Johansson M, Robbins H, Seijo L, Montuenga L, Valencia K. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment. Archivos De Bronconeumología 2024, 60: s67-s76. PMID: 39079848, DOI: 10.1016/j.arbres.2024.07.007.Peer-Reviewed Original ResearchLung cancer screeningLung cancerCancer screeningManagement of lung cancerLDCT-based lung cancer screeningSurgically resected tumorsPresence of metastasesEarly lung cancerCancer-related deathsLung cancer patientsContext of lung cancer screeningDiagnosis to earlier stagesProtein biomarkersResected tumorProtein-based biomarkersTherapeutic optionsAdjuvant strategiesLate diagnosisCancer patientsRecommended management strategiesEarly managementLung cancer detectionRobust biomarkersBenefit patientsCancerWhole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
Patiño-García A, Guruceaga E, Andueza M, Ocón M, Sokoudjou J, de Villalonga Zornoza N, Alkorta-Aranburu G, Uria I, Gurpide A, Camps C, Jantus-Lewintre E, Navamuel-Andueza M, Sanmamed M, Melero I, Elgendy M, Fusco J, Zulueta J, de-Torres J, Bastarrika G, Seijo L, Pio R, Montuenga L, Hernáez M, Ochoa I, Perez-Gracia J. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma. EBioMedicine 2024, 102: 105048. PMID: 38484556, PMCID: PMC10955643, DOI: 10.1016/j.ebiom.2024.105048.Peer-Reviewed Original ResearchHeavy smokersWhole-exome sequencingGermline profilingLung cancerLow riskLung adenocarcinomaCoding genetic variantsIdentification of high-risk subjectsIndividual variantsHigh-risk subjectsSequencing germline DNATobacco consumptionDiscovery cohortAdvanced agePack-yearsExome sequencingProfile of subjectsRisk factorsGenetic variantsYounger ageSmokersFunding bodiesTobaccoCohortAnalysis of individuals
2023
516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Cappuzzo F, Garcia V, Ou S, Brandão M, Sanmamed M, Helissey C, Wislez M, Call J, Grisanti S, Johnson M, Boni V, Jamme P, Monnet I, Siena S, Yan C, Barasa B, Richard B, Joe A, Laus G, Felip E. 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s1671. DOI: 10.1016/j.annonc.2023.10.595.Peer-Reviewed Original Research